‘Product hopping’ under fire in Senate bill

When Allergan withdrew Alzheimer's disease drug Namenda memantine from the market so physicians would prescribe a reformulated once-daily version with a longer patent life, the company was engaging in an anticompetitive practice, according to Sen. John Cornyn (R-Texas). Legislation Cornyn sponsored would

Read the full 427 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE